about
Burkholderia pseudomultivorans sp. nov., a novel Burkholderia cepacia complex species from human respiratory samples and the rhizosphere.Bacteria of the Burkholderia cepacia complex are cyanogenic under biofilm and colonial growth conditions.The mucoid switch in Pseudomonas aeruginosa represses quorum sensing systems and leads to complex changes to stationary phase virulence factor regulationFosmidomycin decreases membrane hopanoids and potentiates the effects of colistin on Burkholderia multivorans clinical isolatesParallel evolution in Pseudomonas aeruginosa over 39,000 generations in vivo.Pseudomonas aeruginosa enhances production of a non-alginate exopolysaccharide during long-term colonization of the cystic fibrosis lung.Swimming motility in a longitudinal collection of clinical isolates of Burkholderia cepacia complex bacteria from people with cystic fibrosis.Whole-Genome Sequencing of Three Clonal Clinical Isolates of B. cenocepacia from a Patient with Cystic FibrosisCystic fibrosis-adapted Pseudomonas aeruginosa quorum sensing lasR mutants cause hyperinflammatory responses.Metabolite profiling to characterize disease-related bacteria: gluconate excretion by Pseudomonas aeruginosa mutants and clinical isolates from cystic fibrosis patientsDeveloping an international Pseudomonas aeruginosa reference panel.Burkholderia species infections in patients with cystic fibrosis in British Columbia, Canada. 30 years' experience.Activity of Tobramycin against Cystic Fibrosis Isolates of Burkholderia cepacia Complex Grown as Biofilms.Comparative Genomics of Burkholderia singularis sp. nov., a Low G+C Content, Free-Living Bacterium That Defies Taxonomic Dissection of the Genus Burkholderia.Randomized controlled trial of biofilm antimicrobial susceptibility testing in cystic fibrosis patients.In vitro efficacy of high-dose tobramycin against Burkholderia cepacia complex and Stenotrophomonas maltophilia isolates from cystic fibrosis patients.Serum susceptibility in clinical isolates of Burkholderia cepacia complex bacteria: development of a growth-based assay for high throughput determination.Total protein extraction and 2-D gel electrophoresis methods for Burkholderia species.Functional quorum sensing systems are maintained during chronic Burkholderia cepacia complex infections in patients with cystic fibrosis.Hypertonic Saline Therapy in Cystic Fibrosis: Do Population Shifts Caused by the Osmotic Sensitivity of Infecting Bacteria Explain the Effectiveness of this Treatment?Differential mucoid exopolysaccharide production by members of the Burkholderia cepacia complex.Defects in a quinol oxidase lead to loss of KatC catalase activity in Pseudomonas aeruginosa: KatC activity is temperature dependent and it requires an intact disulphide bond formation system.Metabolic adaptations of Pseudomonas aeruginosa during cystic fibrosis chronic lung infections.Mucoid morphotype variation of Burkholderia multivorans during chronic cystic fibrosis lung infection is correlated with changes in metabolism, motility, biofilm formation and virulence.Methods for assaying cyanide in bacterial culture supernatant.Surgical masks reduce airborne spread of Pseudomonas aeruginosa in colonized patients with cystic fibrosis.Investigation of the physiological relationship between the cyanide-insensitive oxidase and cyanide production in Pseudomonas aeruginosaComparison of three typing methods for Pseudomonas aeruginosa isolates from patients with cystic fibrosisThe role of mucoidy in virulence of bacteria from the Burkholderia cepacia complex: a systematic proteomic and transcriptomic analysis
P50
Q30656000-3A67095B-CA0F-4B7E-8AAD-24CB60FDEDE7Q33347612-998427B8-66CB-4055-A275-91DE495C7709Q33650160-2447B370-D04C-49EB-988E-52AB6F3609C7Q34057514-6A6C97C7-193E-488D-B4D9-4533DD1539DAQ34128914-A89C5943-FB05-4A81-AF89-0746CCEA1C41Q35064250-92C114C6-3F46-48BA-9457-B481B886FEB9Q35244339-1EFFB035-8ADB-498B-AC5B-932AF82F068CQ35849996-FDA02D78-86C2-43E4-81B9-716BB2F6D221Q36135733-1EBA050D-72A5-40C8-B925-4DD5D171A2EEQ36873652-4A3C13DF-BBB0-47FE-86EE-CB5EA4BE41DAQ37480979-B61A2AB7-9DA3-455F-BBFA-878DFA7C1321Q38283021-3B97A237-9CFC-43C3-9FF0-1406F17196C7Q40936412-1F55EBC6-04A4-48FD-A70E-802730F90445Q41440455-6E498030-0C38-4301-9624-6F40321F7E5CQ41631153-C6AD9E9F-FF04-480A-BF2B-28B126398F73Q41687440-B161E344-0274-43CE-AA3F-B1EE02B08CF5Q41960707-97C24291-CAEF-4BB1-BB1E-C962698A3D90Q41993088-5CC875E3-6138-4428-9412-B4500D7BDDE6Q42710647-A5534A46-3834-4651-95AE-AE22F6CB21AEQ42732058-13543357-848E-4B15-9F09-3BE87ED6FF3DQ43112228-1EBD5A7F-5512-433D-B5B8-D7403FB54047Q46907133-DEEFBB37-CAC7-4007-AF5B-9B29F982874CQ47279278-9985E164-5D69-48F2-B0DB-1565234BEF2FQ48056457-165EC689-C003-4D95-8C41-9F2C0F2C210CQ51694827-80B8E3A0-7C31-434F-977A-54D998A984E3Q51700716-21BCC87C-1D3F-4A26-A170-9F628A34BED9Q58161888-13493F07-99BE-4D50-B300-038868B6A519Q59510305-5325C302-4259-40D8-8A2D-375844BF5552Q84615656-E291DB3C-6E60-42FE-92E6-68B8C42E9DF2
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
James Zlosnik
@ast
James Zlosnik
@en
James Zlosnik
@es
James Zlosnik
@nl
James Zlosnik
@sl
type
label
James Zlosnik
@ast
James Zlosnik
@en
James Zlosnik
@es
James Zlosnik
@nl
James Zlosnik
@sl
prefLabel
James Zlosnik
@ast
James Zlosnik
@en
James Zlosnik
@es
James Zlosnik
@nl
James Zlosnik
@sl
P106
P21
P31
P496
0000-0002-9708-9034